| Literature DB >> 22701466 |
V Saroja Voruganti1, Paul B Higgins, Sven O E Ebbesson, John Kennish, Harald H H Göring, Karin Haack, Sandra Laston, Eugene Drigalenko, Charlotte R Wenger, William S Harris, Richard R Fabsitz, Richard B Devereux, Jean W Maccluer, Joanne E Curran, Melanie A Carless, Matthew P Johnson, Eric K Moses, John Blangero, Jason G Umans, Barbara V Howard, Shelley A Cole, Anthony Gean Comuzzie.
Abstract
The delta-5 and delta-6 desaturases (D5D and D6D), encoded by fatty acid desaturase 1 (FADS1) and 2 (FADS2) genes, respectively, are rate-limiting enzymes in the metabolism of ω-3 and ω-6 fatty acids. The objective of this study was to identify genes influencing variation in estimated D5D and D6D activities in plasma and erythrocytes in Alaskan Eskimos (n = 761) participating in the genetics of coronary artery disease in Alaska Natives (GOCADAN) study. Desaturase activity was estimated by product: precursor ratio of polyunsaturated fatty acids. We found evidence of linkage for estimated erythrocyte D5D (eD5D) on chromosome 11q12-q13 (logarithm of odds score = 3.5). The confidence interval contains candidate genes FADS1, FADS2, 7-dehydrocholesterol reductase (DHCR7), and carnitine palmitoyl transferase 1A, liver (CPT1A). Measured genotype analysis found association between CPT1A, FADS1, and FADS2 single-nucleotide polymorphisms (SNPs) and estimated eD5D activity (p-values between 10(-28) and 10(-5)). A Bayesian quantitative trait nucleotide analysis showed that rs3019594 in CPT1A, rs174541 in FADS1, and rs174568 in FADS2 had posterior probabilities > 0.8, thereby demonstrating significant statistical support for a functional effect on eD5D activity. Highly significant associations of FADS1, FADS2, and CPT1A transcripts with their respective SNPs (p-values between 10(-75) and 10(-7)) in Mexican Americans of the San Antonio Family Heart Study corroborated our results. These findings strongly suggest a functional role for FADS1, FADS2, and CPT1A SNPs in the variation in eD5D activity.Entities:
Keywords: bayesian quantitative trait nucleotide analysis; essential fatty acids; single-nucleotide polymorphisms
Year: 2012 PMID: 22701466 PMCID: PMC3371589 DOI: 10.3389/fgene.2012.00086
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Figure 1Metabolism of essential fatty acids.
Heritabilities and linkage results for D5D and D6D.
| Trait | Mean (SD) | Chr | Location (cM) | LOD score | ||
|---|---|---|---|---|---|---|
| D5D | 0.683 (0.30) | 0.502 (0.15) | 0.00036 | 3 | 97 | 1.615 |
| D6D | 0.0187 (0.01) | 0.897 (0.22) | 0.000275 | 2 | 174 | 1.569 |
| D5D | 8.015 (2.6) | 0.544 (0.11) | 0.0000003 | 11 | 82 | 3.53 |
| D6D | 0.0069 (0.003) | 0.649 (0.12) | 7.4 × 10−9 | 2 | 35 | 1.43 |
*Age, sex, diabetes status, and lipid medication were used as covariates.
Figure 2Genome-wide linkage analysis for erythrocyte D5D localizes a QTL on chromosome 11. The QTL for plasma and erythrocyte D5D estimates on chromosome 11. Solid line, erythrocyte D5D (LOD = 3.5 at 82 cM); dashed line, plasma D5D (LOD = 0.9 at 81 cM).
Figure 3Manhattan plots showing the association of SNPs on CPT1A and FADS1 and FADS2 with erythrocyte D5D. (A) CPT1A and (B) FADS1and FADS2.
Measured genotype association results for SNPs most significantly associated with D5D.
| Gene | SNP | Minor allele (frequency) | MGA ( | |||||
|---|---|---|---|---|---|---|---|---|
| RBC | Plasma | |||||||
| 20:4 ω−6 | 20:3 ω−6 | D5D | 20:4 ω−6 | 20:3 ω−6 | D5D | |||
| rs174541 | A (0.113) | |||||||
| rs174546 | G (0.114) | 0.009 | ||||||
| rs174556 | G (0.122) | 0.009 | ||||||
| rs1535 | A (0.116) | 0.012 | ||||||
| rs174568 | G (0.115) | 0.040 | ||||||
| rs174570 | G (0.161) | 0.009 | 0.015 | |||||
| rs174576 | C (0.116) | 0.012 | ||||||
| rs174579 | G (0.426) | 0.0004 | 0.866 | |||||
| rs968567 | A (0.038) | 0.096 | 0.0003 | 0.032 | 0.023 | 0.625 | 0.042 | |
| rs11228368 | G (0.138) | 0.0004 | 0.157 | |||||
| rs3019594 | A (0.217) | 0.040 | ||||||
| rs613084 | A (0.065) | 0.054 | 0.037 | |||||
*.
Measured genotype association results for SNPs with D6D.
| Gene | SNP | MGA ( | |||||
|---|---|---|---|---|---|---|---|
| RBC | Plasma | ||||||
| 18:3 ω−6 | 18:2 ω−6 | D6D | 18:3 ω−6 | 18:2 ω−6 | D6D | ||
| rs174541 | 0.003 | 0.003 | |||||
| rs174546 | 0.0005 | 0.004 | 0.0008 | ||||
| rs174556 | 0.005 | 0.0016 | |||||
| rs1535 | 0.00029 | 0.003 | 0.0018 | ||||
| rs174568 | 2.7 | 0.003 | 0.002 | ||||
| rs174570 | 0.0033 | 0.056 | 0.002 | 0.0010 | |||
| rs174576 | 0.00033 | 0.003 | 0.0007 | ||||
| rs174579 | 0.232 | 0.932 | 0.960 | 0.171 | 0.239 | ||
| rs968567 | 0.497 | 0.039 | 0.747 | 0.051 | 0.577 | 0.233 | |
| rs11228368 | 0.221 | 0.423 | 0.860 | 0.009 | 0.181 | ||
| rs3019594 | 0.469 | 0.012 | 0.560 | 0.0015 | 0.043 | ||
| rs613084 | 0.119 | 0.881 | 0.086 | 0.301 | |||
*.
Measured genotype association (MGA) results for SNPs with CVD-related phenotypes.
| Gene | SNP | MGA ( | ||||||
|---|---|---|---|---|---|---|---|---|
| ApoA1 | Total cholesterol | Triglycerides | HDL | LDL | Heart rate | Plaque | ||
| rs174541 | 0.010 | 0.623 | 0.120 | 0.0003 | 0.672 | 0.808 | ||
| rs174546 | 0.011 | 0.685 | 0.192 | 0.00057 | 0.565 | 0.856 | ||
| rs174556 | 0.003 | 0.455 | 0.095 | 0.794 | 0.775 | |||
| rs1535 | 0.015 | 0.646 | 0.128 | 0.00047 | 0.665 | 0.664 | ||
| rs174568 | 0.016 | 0.697 | 0.127 | 0.0006 | 0.653 | 0.708 | ||
| rs174570 | 0.011 | 0.119 | 0.234 | 0.001 | 0.484 | 0.213 | ||
| rs174576 | 0.010 | 0.679 | 0.114 | 0.00037 | 0.598 | 0.679 | ||
| rs174579 | 0.249 | 0.930 | 0.508 | 0.097 | 0.149 | 0.0066 | 0.329 | |
| rs968567 | 0.510 | 0.155 | 0.900 | 0.969 | 0.094 | 0.0063 | 0.143 | |
| rs11228368 | 0.026 | 0.289 | 0.439 | 0.057 | 0.780 | 0.056 | ||
| rs3019594 | 0.001 | 0.088 | 0.794 | 0.001 | 0.729 | 0.206 | ||
| rs613084 | 0.001 | 0.177 | 0.997 | 0.670 | 0.0009 | 0.817 | ||
*.
Bayesian quantitative trait nucleotide analysis for erythrocyte and plasma D5D.
| Gene | SNP | Location in the gene | Mean effect size | Posterior probability of a functional effect | AA[ | AB[ | BB[ |
|---|---|---|---|---|---|---|---|
| rs174541 | Flanking 3′ UTR | 0.168 | 1 | 7.65 (2.4)[ | 9.73 (2.1) | 13.56 (3.1) | |
| rs174568 | Flanking 3′ UTR | 0.171 | 1 | 7.65 (2.4) | 9.75 (2.1) | 13.56 (3.1) | |
| rs3019594 | Intron | 0.172 | 0.8 | 7.49 (2.2) | 8.85 (2.4) | 12.40 (3.1) | |
| rs174541 | Flanking 3′ UTR | 0.168 | 0.5 | 0.63 (0.3) | 0.85 (0.3) | 1.47 (0.3) | |
| rs174568 | Flanking 3′ UTR | 0.174 | 0.6 | 0.63 (0.3) | 0.86 (0.3) | 1.47 (0.3) | |
| rs3019594 | Intron | 0.261 | 1 | 0.60 (0.3) | 0.81 (0.3) | 1.19 (0.3) | |
.
.
Figure 4Conditional linkage analysis for erythrocyte D5D on chromosome 11. Linkage analysis conditional on the most significantly associated SNP in (A) CPT1A, (B) FADS1, and (C) FADS2. Solid line, erythrocyte D5D; dashed line, erythrocyte D5D conditional on SNPs.
Measured genotype association results for SNPs with CVD-related phenotypes and .
| Gene | SNP | MGA ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Transcripts | APOA1 | Total cholesterol | Triglycerides | HDL | LDL | Heart rate | Plaque | ||
| rs174546 | 0.055 | 0.044 | 0.730 | 0.058 | 0.163 | 0.039 | 0.518 | ||
| rs174556 | 0.094 | 0.038 | 0.700 | 0.090 | 0.154 | 0.101 | 0.619 | ||
| rs1535 | 0.081 | 0.069 | 0.763 | 0.072 | 0.241 | 0.114 | 0.304 | ||
| rs174570 | 0.168 | 0.772 | 0.710 | 0.282 | 0.709 | 0.041 | 0.461 | ||
| rs174576 | 0.053 | 0.041 | 0.727 | 0.034 | 0.184 | 0.080 | 0.514 | ||
| rs174579 | 0.316 | 0.580 | 0.649 | 0.406 | 0.467 | 0.943 | 0.394 | ||
| rs968567 | 0.933 | 0.034 | 0.333 | 0.518 | 0.032 | 0.370 | 0.882 | ||
| rs11228368 | 0.133 | 0.506 | 0.970 | 0.186 | 0.306 | 0.632 | 0.798 | ||
| rs613084 | 0.281 | 0.883 | 0.771 | 0.234 | 0.336 | 0.587 | 0.821 | ||
*.